|
[Related PubMed/MEDLINE] Total Number of Papers: 11316
|
|
|
[Display Entries]
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of
|
|
|
|
Abbreviation |
: AEs |
Long Form |
: adverse events |
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2023 |
A Comprehensive Analysis of COVID-19 Vaccine Discourse by Vaccine Brand on Korean Twitter: Topic and Sentiment Analysis. |
LDA |
2 |
2023 |
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma. |
PD-L1, SBRT |
3 |
2023 |
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). |
GMCs, IgG, OPA, PCV13, PCVs, PD, PD3, PD4 |
4 |
2023 |
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. |
CB, ctDNA, FAK, MEK, OS, PDAC, PFS |
5 |
2023 |
A post hoc analysis of the EPAZ trial: The role of geriatric variables in elderly soft tissue sarcoma patients on toxicity and outcome. |
IADL, OS, PFS, SAEs |
6 |
2023 |
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. |
LSMCFB, NASH |
7 |
2023 |
A randomized, double-blind, placebo-controlled, phase 2b study of the efficacy and safety of velusetrag in subjects with diabetic or idiopathic gastroparesis. |
GCSI-24H, GE, GES |
8 |
2023 |
A retrospective analysis of the incidence of severe adverse events among recipients of chiropractic spinal manipulative therapy. |
SMT |
9 |
2023 |
Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. |
ARSI, mCRPC, mCSPC, nmCRPC, PRISMA, RCTs, SUCRA |
10 |
2023 |
Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study. |
BRAFV600Emut, mCRC |
11 |
2023 |
Adverse events in neurosurgery: a comprehensive single-center analysis of a prospectively compiled database. |
CSF |
12 |
2023 |
Adverse events unlikely after fine-needle aspiration biopsies of thyroid nodules in patients on low-dose aspirin: a prospective controlled systematic single center analysis. |
FNABs |
13 |
2023 |
An International Evaluation of a Ceramide-Containing Hydrating Cleanser and Moisturizing Cream for the Improvement of Diabetes Mellitus-Related Xerosis. |
CER, DM, DSCS, GAIS, QoL |
14 |
2023 |
Assessment of Efficacy and Safety of mRNA COVID-19 Vaccines in Children Aged 5 to 11 Years: A Systematic Review and Meta-analysis. |
mRNA, ORs |
15 |
2023 |
Automated Detection of Patient Harm: Implementation and Prospective Evaluation of a Real-Time Broad-Spectrum Surveillance Application in a Hospital With Limited Resources. |
PPV |
16 |
2023 |
Bolus versus Continuous Intravenous Delivery of Doxorubicin in Soft Tissue Sarcomas: Post Hoc Analysis of a Prospective Randomized Trial (SARC021/TH CR-406). |
BOL, CIV, DOX, OS, PFS, STS |
17 |
2023 |
Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma. |
CPH, PFS, RCC |
18 |
2023 |
Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries. |
CV, EV, FDA, HT, PCa, PRR |
19 |
2023 |
Categorization of Adverse Events Reported to the FDA Pertaining to Tibia Intramedullary Nailing. |
FDA, IMN |
20 |
2023 |
Clinical Value of IL6R Gene Variants as Predictive Biomarkers for Toxicity to Tocilizumab in Patients with Rheumatoid Arthritis. |
bDMARD, IL-6, IL-6R, RA, SNPs |
21 |
2023 |
Comparison of endoscopic full-thickness resection and ligation-assisted endoscopic full-thickness resection for small (≤ 1.5 cm) gastric subepithelial tumors originating from muscularis propria. |
EFTR, SET-MPs |
22 |
2023 |
Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. |
ACR20, MTX, RA, RCTs, SUCRA |
23 |
2023 |
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2. |
LNP, saRNA |
24 |
2023 |
COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial. |
allo-HSCT |
25 |
2023 |
Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study. |
BCPNN, JAERS, MHRA, PRR, ROR |
26 |
2023 |
Detection and endoscopic classification of intraductal neoplasms of the bile duct by peroral cholangioscopy with narrow-band imaging (with videos). |
IN-B, ISL-Bs, NBI, POC, POC-FB |
27 |
2023 |
Diagnostic outcome and safety of plugged liver biopsy in high-risk patients: a systematic review and meta-analysis. |
CI, OR, PLB, TJLB |
28 |
2023 |
Diarrhea and colitis related to immune checkpoint inhibitor and BRAF/MEK inhibitor therapy. |
ICI, MEK |
29 |
2023 |
Effect of arotinolol on chronic heart failure: A systematic review and meta-analysis of randomized controlled trials. |
BNP, CI, hs-CRP, LVEDD, LVEDV, LVEF, RCTs, SMD, SV |
30 |
2023 |
Effectiveness of electroacupuncture versus prucalopride for women with severe chronic constipation: secondary analysis of a randomized controlled trial. |
CSBMs, EA, SCC |
31 |
2023 |
Efficacy and safety comparison of PD-1 inhibitors vs. PD-L1 inhibitors in extensive-stage small-cell lung cancer: a retrospective comparative cohort study. |
CI, ES-SCLC, HR, ICIs, mOS, mPFS, OS, PD-1, PD-L1, PFS |
32 |
2023 |
Efficacy and safety of 1.5% levofloxacin otic solution for the treatment of otitis media in a multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase III study. |
AOM, BICRC, CSOM, LVFX |
33 |
2023 |
Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis. |
CIs, DCR, EGFR, HR, NMA, NSCLC, ORR, OS, PFS, PFS, RR |
34 |
2023 |
Efficacy and Safety of Blinatumomab for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Systemic Review and Meta-Analysis. |
BM, CR, CRS, MRD, OS, RFS |
35 |
2023 |
Efficacy and safety of Ciprofol for procedural sedation and anesthesia in non-operating room settings. |
FB |
36 |
2023 |
Efficacy and safety of ciprofol versus propofol for the induction of anesthesia in adult patients: a multicenter phase 2a clinical trial. |
MOAA/S |
37 |
2023 |
Efficacy and Safety of COVID-19 Vaccination in Older Adults: A Systematic Review and Meta-Analysis. |
GMT, RCTs |
38 |
2023 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. |
CG, CP, OS, PFS, TNBC |
39 |
2023 |
Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial. |
BQT, H. pylori, HDDT, ITT, mITT, PP, PPI |
40 |
2023 |
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). |
AD, IL, LEB, PBO, TCS, TEAEs |
41 |
2023 |
Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. |
CI, CR, DCR, HCC, HR, OR, ORR, OS, PFS, PR |
42 |
2023 |
Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer. |
CCRT, CRR, LACC, ORR, OS, PFS |
43 |
2023 |
Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. |
DCR, MPM, ORR, PFS |
44 |
2023 |
Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. |
ARR, DMDs, EDSS, MS, RRMS, RTX |
45 |
2023 |
Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis (RA): A Retrospective Study From Two Centers in Jeddah, Saudi Arabia. |
DAS, ESR, HDL, JAK, LDL, RA |
46 |
2023 |
Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis. |
EGFR, HR, ORR, OS, TKIs, VEGF |
47 |
2023 |
Efficacy of intra-arterial chemotherapy with sequential anti-PD-1 antibody in unresectable gastric cancer: A retrospective real-world study. |
IAC, OS, PFS, TIME, TLSs |
48 |
2023 |
Endoscopic submucosal dissection using an ultrathin endoscope for superficial pharyngeal cancer: a prospective feasibility study (with video). |
ESD |
49 |
2023 |
Endoscopic Ultrasound Guided Biliary Drainage in Malignant Distal Biliary Obstruction. |
EC-LAMS, EUS, EUS-BD, LAMS, MBO, PTBD, QoL |
50 |
2023 |
Endoscopic ultrasound-guided gastroenterostomy for the management of gastric outlet obstruction: A large comparative study with long-term follow-up. |
ES, EUS-GE, GOO, LOS, surgical-GE |
51 |
2023 |
Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration. |
DED, PK |
52 |
2023 |
Exploring procedure duration and risk for serious adverse events during congenital cardiac catheterization. |
--- |
53 |
2023 |
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations. |
DLT, MTD |
54 |
2023 |
Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study. |
BCLC, CI, DCR, GSMs-TACE, HCC, IQR, ORR, OS, PFS |
55 |
2023 |
Hiatal hernia repair with transoral incisionless fundoplication versus Nissen fundoplication for gastroesophageal reflux disease: A retrospective study. |
GERD, HH, LNF, TIF |
56 |
2023 |
Hospitalisations Related to the Combination of ACE Inhibitors and/or Angiotensin Receptor Blockers with Diuretics and NSAIDs: A Post Hoc Analysis on the Risks Associated with Triple Whammy. |
ED, RORs |
57 |
2023 |
Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system. |
FAERS |
58 |
2023 |
Immunotherapy as a Promising Option for the Treatment of Advanced Chordoma: A Systemic Review. |
DLT, ICIs, OS, PFS, RECIST |
59 |
2023 |
Incidence of adverse events for procedural sedation and analgesia for cardioversion using thiopental in elderly patients: a multicenter prospective observational study. |
JPSTAR, PSA |
60 |
2023 |
Integrated safety and efficacy analysis of dasiglucagon for treatment of severe hypoglycaemia in individuals with type 1 diabetes. |
SH, T1D |
61 |
2023 |
Integrative treatment program for the treatment of children with autism spectrum disorder: A prospective observational case series. |
ABC, ASD, CARS, HM, SET |
62 |
2023 |
LIQUID - Treatment of high-grade dural arteriovenous fistulas with Squid liquid embolic agent: a prospective, observational multicenter study. |
DAVFs, mRS |
63 |
2023 |
Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study. |
cDAPSA, LDA, MDA/VLDA, PS, TNFi |
64 |
2023 |
Long-term Evaluation of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Biological Disease-modifying Antirheumatic Drugs. |
ACR, DMARDs, RA |
65 |
2023 |
Long-term Safety and Efficacy of E6011, an Anti-fractalkine Monoclonal Antibody, in Patients with Rheumatoid Arthritis Inadequately Responding to Methotrexate. |
ACR, MTX, RA |
66 |
2023 |
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial. |
ORR12w, OS, PFS, VIT |
67 |
2023 |
Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis. |
MDR-TB |
68 |
2023 |
Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. |
IRs, UC |
69 |
2023 |
Multicentre positive deviance to reduce adverse events and length of stay after pulmonary resection. |
LOS, PD |
70 |
2023 |
Neoadjuvant checkpoint blockade in combination with Chemotherapy in patients with tripe-negative breast cancer: exploratory analysis of real-world, multicenter data. |
DFS, ORR, pCR, TNBC |
71 |
2023 |
Nocebo response intensity and influencing factors in the randomized clinical trials of irritable bowel syndrome: A systematic review and meta-analysis. |
IBS |
72 |
2023 |
Novel Image-Guided Flexible-Probe Transbronchial Microwave Ablation for Stage 1 Lung Cancer. |
tMWA |
73 |
2023 |
Pembrolizumab combined with paclitaxel and platinum as induction therapy for locally advanced esophageal squamous cell carcinoma: a retrospective, single-center, three-arm study. |
DCR, ESCC, iPR, iSD, MPR, ORR, pCR, PFS |
74 |
2023 |
Pharmacokinetic and bioequivalence of lenalidomide in multiple myeloma patients. |
AUC, CI, MM |
75 |
2023 |
Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with breast, colorectal or gastric cancer under fed condition: A multicentric, randomized, open-label, single-dose, two-period, two-way crossover clinical trial. |
CIs, GMRs, SAEs |
76 |
2023 |
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. |
DLTs, NSCLC |
77 |
2023 |
Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. |
CI, LSVT BIG, MD, NMAs, PD, PDQ-39, QoL, RCTs, RoB 2 |
78 |
2023 |
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System. |
BCPNN, FAERS, IQR, MGPS, ROR, SOC |
79 |
2023 |
Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study. |
DCR, HCC, HR, ICIs, mOS, mPFS, NLR, ORR, TACE, TKI, uHCC |
80 |
2023 |
Prophylaxis of Neutropenia with Lipegfilgrastim in Breast Cancer Patients with Dose-Dense Chemotherapy: Results of a Noninterventional Study on Therapeutic Routine in Germany (NADENS). |
DD, IDD, NADENS, NIS |
81 |
2023 |
Psychological Distress and Physical Adverse Events of COVID-19 Vaccination among Healthcare Workers in Taiwan. |
GEE, HCWs, NCKUH |
82 |
2023 |
Reactogenicity and safety of second trimester maternal tetanus, diphtheria and acellular pertussis vaccination in the Netherlands. |
GA, Tdap |
83 |
2023 |
Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data. |
OS, PFS, PR, RRMM |
84 |
2023 |
Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan. |
ADRs, FVC, IPF |
85 |
2023 |
Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. |
HCC, TT |
86 |
2023 |
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea. |
ADRs, AS, CD, CDAI, IFX, KBASDAI, PMS, PsA, PsO, RA, SAEs, UC |
87 |
2023 |
Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. |
AITL, aNHL, CLL/SLL, CR, FL, iNHL, MCL, mPFS, ORR, OS, PDR, PR, RR, T-NHL |
88 |
2023 |
Safety and Efficacy of Patiromer in Hyperkalemic Patients with CKD: A Pooled Analysis of Three Randomized Trials. |
RAASi |
89 |
2023 |
Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. |
IgG, NAb, pIMDs, RSV, SAEs |
90 |
2023 |
Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study. |
atyMBCs, CoV-2 Nab, COVID-19, HC, MBC, MS, RBD |
91 |
2023 |
Safety and performance of the Spectra Optia apheresis system for white blood cell depletion in patients with elevated white blood cell counts. |
WBC, WBCD |
92 |
2023 |
Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer. |
3wkCP, chemo-IO, DCR, ORR, OS, PFS, wkCP |
93 |
2023 |
Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022. |
AESI, PTs, VAERS |
94 |
2023 |
Safety of intrahospital transport for MR or CT scans in ventilated pediatric intensive care patients with congenital heart disease. |
CHD, MAP |
95 |
2023 |
Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. |
mCRPC |
96 |
2023 |
Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response. |
CR, CT, DWI, HCC, mRECIST, MRI, OS, PR, SD, TACE, TTP |
97 |
2023 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-C5a Antibody BDB-001 for Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial in Healthy Chinese Adults. |
AUC0-480h, C5a, COVID-19, IgG4, SAEs, TMDD |
98 |
2023 |
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience. |
CPs, PROs, SEs |
99 |
2023 |
Stereotactic body radiation therapy (SBRT) as salvage treatment for early stage lung cancer with interstitial lung disease (ILD): An observational and exploratory case series of non-asian patients. |
ILD, LC, SBRT |
100 |
2023 |
Stretching, Bracing, and Devices for the Treatment of Osteoarthritis-Associated Joint Contractures in Nonoperated Joints: A Systematic Review and Meta-Analysis. |
MD, OA, ROM |
|